NEW YORK, NY, Remepy, announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M.
Remepy, a pioneer in 'hybrid drugs,' announced that it has successfully closed a $10M seed investment round, which together with earlier funding totals $15M. The round was led by NFX, joined by Vine Ventures, PsyMed Ventures, Supernode Ventures and Firstime Ventures, joining previous pre-seed lead investor TechAviv as well as Fresh.fund, Samsung Next, StageNext Fund and 97212 Ventures.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
